Novartis Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).

1,375 total trials 110 currently recruiting 944 completed early-phase tilt top decile by trial count

Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.

Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.

Top-decile sponsor footprint

Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,375 total, page 26 of 28

TERMINATED Phase 3

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

NCT00272987
COMPLETED Phase 2

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

NCT00263588
COMPLETED Phase 3

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

NCT00248170
COMPLETED Phase 1

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
COMPLETED Phase 2

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

NCT00219297
COMPLETED Phase 4

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

NCT00267176
COMPLETED Phase 3

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

NCT00262990
COMPLETED Phase 3

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
COMPLETED Phase 3

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
TERMINATED Phase 1

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

NCT00251433
COMPLETED Phase 3

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
COMPLETED Phase 4

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

NCT00229138
COMPLETED Phase 1

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

NCT00231166
COMPLETED Phase 4

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00117507
COMPLETED Phase 1

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

NCT00135005
COMPLETED Phase 2

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
COMPLETED Phase 2

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00124280
COMPLETED Phase 1

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

NCT00456833
TERMINATED Phase 3

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

NCT00124748
COMPLETED Phase 3

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

NCT00351507
COMPLETED Phase 2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617
COMPLETED Phase 1

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

NCT00109707
TERMINATED Phase 1

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

NCT00108108
COMPLETED Phase 2

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

NCT00107016
COMPLETED Phase 3

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

NCT00142298
COMPLETED Phase 3

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

NCT00106340
COMPLETED Phase 2

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

NCT00108836
COMPLETED Phase 3

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

NCT00098059
COMPLETED Phase 4

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

NCT00219284
COMPLETED Phase 3

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00101803
COMPLETED Phase 2

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670
COMPLETED Phase 4

Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

NCT00136851
COMPLETED Phase 4

Non-small Cell Lung Cancer Registry

NCT00099541
COMPLETED Phase 3

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
COMPLETED Phase 3

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229
TERMINATED Phase 3

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

NCT00171431
COMPLETED Phase 3

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107926
COMPLETED Phase 4

A Multiple Myeloma Trial in Patients With Bone Metastases

NCT00104104
COMPLETED Phase 2

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

NCT00097955
COMPLETED Phase 3

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

NCT00171210
COMPLETED Phase 3

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268
TERMINATED Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

NCT00279773
COMPLETED Phase 2

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730
COMPLETED Phase 2

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

NCT00171951
COMPLETED Phase 3

A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

NCT00098007
COMPLETED Phase 1

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

NCT00093639
COMPLETED Phase 3

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

NCT00097968
COMPLETED Phase 2

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00098228
COMPLETED Phase 2

Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

NCT00131118
COMPLETED Phase 3

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808
← Previous Page 26 of 28 Next →

Phase Distribution

PhaseTrial count
Phase 1 326
Phase 2 450
Phase 3 393
Phase 4 77

Therapeutic Areas

Non-Small Cell Lung Cancer 10
Breast Cancer 9
Multiple Sclerosis 9
Chronic Spontaneous Urticaria 8
Hypertension 7
Melanoma 7
Relapsing Multiple Sclerosis 6
Carcinoma, Non-Small Cell Lung 6
Hidradenitis Suppurativa 5
Sickle Cell Disease 5

What is open in the Novartis Pharmaceuticals pipeline

110 recruiting of 1,375 indexed (8% open); 944 completed (69%).

Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).

Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Novartis Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Novartis PharmaceuticalsGlaxoSmithKlineEli Lilly and CompanyUniversity of PennsylvaniaUniversity of MichiganArcutis BiotherapeuticsMedtronic EndovascularPenumbraSK Life Science
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,375 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Novartis Pharmaceuticals page

1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.

  • 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.